Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.

Current iron chelation therapy consists primarily of DFO (desferrioxamine), which has to be administered via intravenous infusion, together with deferiprone and deferasirox, which are orally-active chelators. These chelators, although effective at decreasing the iron load, are associated with a number of side effects. Grady suggested that the combined administration of a smaller bidentate chelator and a larger hexadentate chelator, such as DFO, would result in greater iron removal than either chelator alone [Grady, Bardoukas and Giardina (1998) Blood 92, 16b].

The fenton activity of iron(III) in the presence of deferiprone.

Hydroxyl radical production from a range of clinically relevant iron chelators in the presence of hydrogen peroxide was measured using the deoxyribose oxidation assay. Hydroxyl radical production from an iron complex is dependent on whether the ligand is able to completely surround the iron, thereby preventing access of reductants to the coordinated iron cation. The partially coordinated [(deferiprone)(2)Fe(III)](+) complex is able to generate hydroxyl radicals in the presence of oxidants, whereas the fully coordinated [(deferiprone)(3)Fe(III)](0) complex is not.

Chronic fatigue syndrome.

Chronic fatigue syndrome (CFS) is thought to have a worldwide prevalence of 0.4-1% with approximately 240,000 patients in the UK. Diagnosis is based on clinical criteria and critically depends on exclusion of other physical and psychiatric diseases.

Current research priorities in chronic fatigue syndrome/myalgic encephalomyelitis: disease mechanisms, a diagnostic test and specific treatments.

Chronic fatigue syndrome (CFS) is an illness characterised by disabling fatigue of at least 6 months duration, which is accompanied by various rheumatological, infectious and neuropsychiatric symptoms. A collaborative study group has been formed to deal with the current areas for development in CFS research--namely, to develop an understanding of the molecular pathogenesis of CFS, to develop a diagnostic test and to develop specific and curative treatments. Various groups have studied the gene expression in peripheral blood of patients with CFS, and from those studies that have been confirmed using polymerase chain reaction (PCR), clearly, the most predominant functional theme is that of immunity and defence.